EXE: Q2 2026 Adjusted EBITDA jumped 71.7% to $68.3M, fueled by acquisitions and strong home health growth
Extendicare Inc. (EXE) reported Q2 2026 adjusted EBITDA up 71.7% year over year to $68.3M, citing acquisitions and organic home health growth. Revenue increased 59.4% to $611.0M. The company completed a $570M acquisition and a $450M unsecured notes offering, according to its Aug. 7, 2026 earnings release.





